Value & Outcomes Spotlight is an ISPOR publication for the global HEOR community. Value & Outcomes Spotlight provides enhanced content on health policy and methodological issues and independent contributions from the field, as well as the scientific program of ISPOR Annual Meetings/Congresses/Regional Conferences, plus ISPOR news from around the world.
To receive Value & Outcomes Spotlight and other member benefits, join ISPOR.
Value & Outcomes Spotlight
January/February 2018 Vol. 4, No. 1
In this issue of Value & Outcomes Spotlight, we introduce a new layout for 2018, highlighting some new features and sections for our readers to enhance their reading experience. Newly included sections for VOS include ISPOR Central, which includes an ISPOR Speaks section (this issue featuring ISPOR Executive Director & CEO Nancy Berg), and HEOR News and Research Round-Up, which provides the latest in news and research, respectively. The ISPOR Central section also still provides members with future meetings, education, and other ISPOR activities.
As always, VOS continues to strive in providing the most up-to-date topics in HEOR content. We now also begin another new section of sorts in providing a theme for each one of our issues. In this current issue, we focus on Cancer Immunotherapies, with a feature article on the value of these therapies with interviews from prominent leaders in the field such as Michael Drummond, Ravinder Dhawan, and Isao Kamae. We complement this comprehensive piece with related articles on immuno-oncology data, oncology patient-reported outcome measures, and challenges and approaches for overall survival extrapolations, as well as a new “By the Numbers” graphic, contributed by the ISPOR Student Network.
Finally, we publish a Q&A with F. Reed Johnson who led the first FDA sponsored study on patients’ willingness to accept benefit risk tradeoffs for new health technologies on discrete choice experiment methods.
We hope you enjoy the new and improved Value & Outcomes Spotlight! As always, we welcome your feedback and encourage you to email us at email@example.com
David Thompson, PhD
Value & Outcomes Spotlight Editor-in-Chief
The new classes of cancer immunotherapies hold great, exciting clinical promise across a number of cancer types, with the potential of extending the lives of patients who previously had no options. However, these drugs also come with an eye-watering sticker price, with courses of treatment costing hundreds of thousands of dollars.
Research of immunotherapies in oncology requires alternative methods of observation and analysis to accurately assess their outcomes, due to their delayed clinical benefits and durable responses relative to conventional cytotoxic therapy (chemotherapy).
Dr. Lambert highlights, in this brief communication, the need to adjust PRO assessments and strategies in oncology trials to the evolving era of cancer care and the development of personalized medicine. Innovative approaches, including qualitative interviews, are becoming essential to complement data from legacy questionnaires to document patient-perceived treatment experience and benefits.
In this article, Huang et al introduce a comprehensive list of models for extrapolating overall survival data and illustrate their application to a clinical trial data set. They also compare and contrast the model outcomes and provide insights on the tradeoffs in model selection in the context of the probable underlying biomedical processes for immuno-oncology treatments.
In this article, the opportunities and challenges associated with gene therapy are explored from the innovator, the payer, and the European perspectives.